DOCTOR – About the myDNA test
About our test
The myDNA Medication tests use pharmacogenomics to identify variations in a number of genes that influence medication response.
Currently, myDNA Medication reports concentrate on the genes encoding the metabolising enzymes (i.e. CYP450 enzymes) which are found mainly in the liver as well as the gut wall. These genetic variations predict the level of enzyme activity which in turn results in increased or decreased plasma concentrations and drug exposure.
Increased plasma concentrations, due to reduced enzyme activity, can lead to adverse effects. Reduced plasma concentrations, due to increased enzyme activity, can lead to poor therapeutic response.
myDNA offers a multiple gene medication test, which covers multiple medication categories (currently in excess of 80 medications). If information on medications in a specific therapeutic area is of interest, myDNA offers four single category medication reports as shown below.
- Pain Medication
- Mental health medications
- Cardiovascular Medications
- Gastrointestinal medications.
Enzyme function can also be affected by factors other than genotype, including age, the effect of co-administered drugs (i.e. drug-drug interactions), and the presence of liver disease. These should be taken into account when considering the myDNA Medication Reports.
Reports must be delivered by a suitable healthcare professional. myDNA provides training for medical staff to assist in the understanding of these reports. If you would like to know more about this training, please email us: [email protected].
DOCTOR – Pharmacogenomic
Hear from our Associate Professor Les Sheffield
DOCTOR – Who is it Recommended For
The patients likely to benefit from myDNA testing include those who are:
- Experiencing side effects to specific medications
- Not responding to specific medications
- Requiring doses of specific medications outside the recommended range
- Planning to start on a new medication covered by the myDNA test
- Taking multiple medications
Each person who takes a myDNA test will receive a highly customised medication report and ongoing access to their Explore myDNA – a secure online portal that provides information relevant to the person’s genetic profile.
DOCTOR – Evidence
EVIDENCE BEHIND PHARMACOGENOMIC TESTING
In our reports, myDNA references the guidelines of the Royal Dutch Pharmacists Association – Pharmacogenetics Pharmacogenomics Working Group and the Clinical Pharmacogenetics Implementation Consortium (CPIC). Generally, the emphasis is on CPIC guidelines, given their more recent publication.
The following published guidelines contain evidence for gene-drug associations for which dosage adjustments have been recommended. These can be accessed online at CPIC.
- CPIC Guideline for CYP2D6 and CYP2C19 genotypes and dosing of Tricyclic Antidepressants
- CPIC Guideline for CYP2D6 and CYP2C19 genotypes and dosing of Selective Serotonin Reuptake Inhibitors (SSRIs)
- Dutch Pharmacogenetics Working Group guidelines which include a number of antidepressant and antipsychotic medications
MEDS – Stories
Rachel shares her story
Joy shares her story
DOCTOR – How to Order
How to order
Offering the myDNA test to your patients is simple and can be done using the following methods:
- Cheek swabs tests can be purchased directly by patients, following referral from their prescriber, from their nearest myDNA Accredited Pharmacy. The sample is then sent to the lab for analysis and a personalised report is sent back to the requesting doctor and pharmacy. Reports start at just $99 for a single category medication report and $149 for the multiple gene pharmacogenomic report.
- Blood tests can be ordered through our pathology partner Australian Clinical Labs for $169 for the multiple gene pharmacogenomics report. Other pathology providers may add an additional charge for blood collection. The 4mL EDTA sample is then sent to the lab for analysis and a personalised report is sent back to the requesting doctor.